Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma...